(SeaPRwire) – By: Maxwell Vance
This isn’t a strategic pivot. It’s a distress signal wrapped in a related-party transaction. IM Cannabis Corp.’s plan to sell its European arm to its own CEO’s private holding company is a textbook maneuver for a firm backed into a financial corner. The press release talks of streamlining and focus, but the legal fine print screams “serious financial difficulty.” When a public company invokes the “financial hardship” exemption to bypass minority shareholder approval, it’s not planning for growth. It’s performing emergency triage on a balance sheet that’s likely hemorrhaging cash. The real story here isn’t the geographic retreat; it’s the admission of a crisis severe enough to justify handing assets to the boss.
[Official Announcement Facts]
On June 18, 2026, IM Cannabis announced a non-binding letter of intent. The buyer is Slil.com Holding Ltd., a private entity owned by IMC’s CEO, Oren Shuster. The asset for sale is I.M.C. Holdings Ltd., which holds the company’s European operations. This includes Adjupharm GmbH in Germany, plus interests in Xinteza API Ltd. and Shiran Societe Anonyme. The purchase price is not cash. Slil will assume approximately CAD$10.5 million of IMC’s debt. This breaks down to CAD$7.5 million in retained liabilities and CAD$3 million in short-term liabilities. Post-sale, IMC keeps its Israeli subsidiaries: Focus Medical Herbs Ltd., Rosen High Way Ltd., R.A. Yarok Pharm Ltd., and Rivoly Trading and Marketing Ltd. The board has formed a special committee of independent directors. They have also hired Beta Finance T.Y.S Ltd. to prepare a fairness report. The deal remains subject to a definitive agreement and regulatory clearances.
[True Commercial Intentions]
The company isn’t selling for growth capital. It’s selling for survival. The CAD$10.5 million debt assumption is the entire consideration. This reveals the European unit likely carries negative equity. No outside buyer would touch it with that debt load. By moving it to the CEO’s private books, IMC gets a cleaner public balance sheet instantly. The “streamlining” is a euphemism for cutting off a limb to save the body. The retention of Israel is telling. It’s the home market, possibly the only one with positive cash flow or a defensible position. Germany and Europe are being jettisoned as cost centers. The use of the MI 61-101 “financial hardship” exemption is the most critical data point. To legally bypass shareholder votes, the board must formally state the company is in serious financial difficulty. This transaction is their prescribed cure. It’s a controlled demolition of the corporate structure to prevent an uncontrolled collapse.
The immediate target is clear: stop the bleeding. The CAD$10.5 million debt removal is a lifeline. But this kind of related-party deal at a non-cash price sets a dangerous precedent. It effectively transfers corporate assets to insiders under duress. Minority shareholders are left with a shrunken, Israel-focused company. They have no vote on the matter due to the legal exemption. The CEO, through Slil, acquires the European operations and their associated debt. He bets he can turn them around privately, away from public market scrutiny. For the public IMC, the path forward is a desperate gamble on the Israeli medical cannabis market alone. The promised “pursuit of new investment opportunities” rings hollow when the company just used a hardship clause to sell assets to its CEO. The market share reshuffling here is internal and punitive. IMC is exiting the European stage not with a bang, but with a legal waiver.
Author bio: Maxwell Vance, a hedge fund manager specializing in distressed asset acquisition and proxy fights, with two decades of experience dissecting boardroom maneuvers in struggling public companies.